Cart
sales@molnova.com
Icrucumab
CAS No. 1024603-92-6
Icrucumab( —— )
Catalog No. M36749 CAS No. 1024603-92-6
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 342 | Get Quote |
|
| 5MG | 618 | Get Quote |
|
| 10MG | 941 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIcrucumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionIcrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.
-
DescriptionIcrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1024603-92-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.?
molnova catalog
related products
-
Tyrosine kinase-IN-1
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor(KDR Flt-1 FGFR1 and PDGFRα with IC50s of 4nM 20nM 4nM 2 nM respectively).
-
VEGFR-3-IN-1
VEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.
-
PKI-166
PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.
